HQK 1001 / Viracta Therap - LARVOL DELTA

Foetal haemoglobin inducers for reducing blood transfusion in non-transfusion-dependent beta-thalassaemias. (PubMed, Cochrane Database Syst Rev) - "We are uncertain whether any of the eight HbF inducers in this review have a beneficial effect on people with NTDβT. For each of these HbF inducers, we found only one or at the most two small studies. There is no information on whether any of these HbF inducers have an effect on our primary outcome, blood transfusion. For the second primary outcome, haemoglobin, there may be small differences between intervention groups, but these may not be clinically meaningful and are of low- to very low-certainty evidence. Data on adverse effects and optimal doses are limited. Five studies are awaiting classification, but none are ongoing."

Journal • Review • Beta-Thalassemia • Cardiovascular • Gastrointestinal Disorder • Hematological Disorders • Hypertension • Neutropenia • Pain • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Thrombocytopenia

A study of HQK-1001 in patients with sickle cell disease (clinicaltrials.gov) - P2, N=52; Active, not recruiting -> Completed

Trial completion • Hematological Malignancies